More from Curaleaf

Research publication: An Analysis of Clinical Outcomes of Medicinal Cannabis Therapy for Attention-Deficit/Hyperactivity Disorder

This research addresses the gap in current medical knowledge – the lack of high-quality clinical evidence and prospective studies on the use of medical cannabis products in patients with ADHD-related symptoms. Notably, there has been a significant absence of published clinical studies examining the long-term outcomes of adults treated with medical cannabis products.

This new study therefore aimed to analyse the health-related quality of life and safety outcomes in people with ADHD who are prescribed medical cannabis products and have enrolled in the UK Medical Cannabis Registry.

Read the full study here: UK Medical Cannabis Registry: An analysis of clinical outcomes of medicinal cannabis therapy for attention‐deficit/hyperactivity disorder – Ittiphakorn – Neuropsychopharmacology Reports – Wiley Online Library

Learn more about the UK Medical Cannabis Registry and it’s research here: Real World Evidence | Medical Cannabis Clinics UK (sapphireclinics.com)

Latest News

10/02/2024

Curaleaf International (the “Company”), part of Curaleaf Holdings (TSX:CURA) and Europe’s largest vertically integrated …

08/01/2024

Curaleaf International, Europe’s largest vertically integrated cannabis company, is pleased to announce that its …

31/08/2023

Miles Worne, President of Curaleaf International, spoke to the Financial Times about the upcoming changes …

You are about to leave the Curaleaf International website.